Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics

Progress in Retinal and Eye Research

Volumn 29, Issue 6, 2010, Pages 466-475

  Laude, Augustinus ^a,b   Tan, Lay Ean ^c   Wilson, Clive G ^c   Lascaratos, Gerassimos ^a   Elashry, Mohammed ^a   Aslam, Tariq ^d   Patton, Niall ^e   Dhillon, Baljean ^a  

^a PRINCESS ALEXANDRA EYE PAVILION   (United Kingdom)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Injection; Intravitreal therapy; Pharmacokinetics; Vitreous

Indexed keywords

AMIKACIN; ANTIGLAUCOMA AGENT; BEVACIZUMAB; CARBENICILLIN; CARBONATE DEHYDRATASE INHIBITOR; DEXAMETHASONE; GANCICLOVIR; GENTAMICIN; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VANCOMYCIN; VASCULOTROPIN INHIBITOR;

AQUEOUS HUMOR FLOW; BLOOD EYE BARRIER; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIFFUSION; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; EXPERIMENTAL ANIMAL; GEOMETRY; GLAUCOMA; HUMAN; INJECTION SITE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; LENS; LIQUEFACTION; LOADING DRUG DOSE; METHODOLOGY; MONKEY; NEEDLE; NEOVASCULARIZATION (PATHOLOGY); NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RABBIT; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; SCINTIGRAPHY; TECHNIQUE; TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING; VISCOSITY; VISUAL SYSTEM PARAMETERS; VITRECTOMY; VITREOUS BODY; VOLUMETRY;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; HUMANS; INDIVIDUALITY; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MODELS, BIOLOGICAL; VITRECTOMY; VITREOUS BODY;

EID: 78650794789     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2010.04.003     Document Type: Review

References (80)

1. Adelman, R., 2009. Persistent ocular hypertension associated with intravitreal anti-VEGF. In: American Academy of Ophthalmology Joint Annual Meeting San Francisco, USA.
2. Aguilar H.E., Meredith T.A., el-Massry A., Shaarawy A., Kincaid M., Dick J., Ritchie D.J., Reichley R.M., Neisman M.K. Vancomycin levels after intravitreal injection. Effects of inflammation and surgery. Retina 1995, 15:428-432.
3. Avci B., Avci R., Inan U.U., Kaderli B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest. Ophthalmol. Vis. Sci. 2009, 50:3438-3446.
4. Bakri S.J., McCannel C.A., Edwards A.O., Moshfeghi D.M. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:955-958.
5. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Singh R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007, 114:855-859.
6. Barza M., Kane A., Baum J. The effects of infection and probenecid on the transport of carbenicillin from the rabbit vitreous humor. Invest. Ophthalmol. Vis. Sci. 1982, 22:720-726.
7. Barza M., Kane A., Baum J. Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. Invest. Ophthalmol. Vis. Sci. 1983, 24:1602-1606.
8. Benz M.S., Albini T.A., Holz E.R., Lakhanpal R.R., Westfall A.C., Iyer M.N., Carvounis P.E. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006, 113:1174-1178.
9. Boon C.J., Crama N., Klevering B.J., van Kuijk F.J., Hoyng C.B. Reflux after intravitreal injection of bevacizumab. Ophthalmology 2008, 115:1270. author reply 1271.
10. Bressler N.M. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009, 116:S15-23.
11. Cheng C.K., Peng P.H., Tien L.T., Cai Y.J., Chen C.F., Lee Y.J. Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection. Retina 2009, 29:306-312.
12. Chin H.S., Park T.S., Moon Y.S., Oh J.H. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005, 25:556-560.
13. Chuang G.S., Rogers G.S., Zeltser R. Poiseuille's law and large-bore needles: insights into the delivery of corticosteroid injections in the treatment of keloids. J. Am. Acad. Dermatol. 2008, 59:167-168.
14. Cobo L.M., Forster R.K. The clearance of intravitreal gentamicin. Am. J. Ophthalmol. 1981, 92:59-62.
15. Dadgostar H., Ventura A.A., Chung J.Y., Sharma S., Kaiser P.K. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009, 116:1740-1747.
16. Drolet D.W., Nelson J., Tucker C.E., Zack P.M., Nixon K., Bolin R., Judkins M.B., Farmer J.A., Wolf J.L., Gill S.C., Bendele R.A. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res. 2000, 17:1503-1510.
17. Eter N. Ranibizumab for Neovascular ARMD: Results of the EXCITE and SUSTAIN Studies 2008, German Retina Society, Wurzburg, Germany.
18. Falavarjani K.G., Modarres M., Nazari H. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy. Eye 2010, 24:717-719.
19. Ficker L., Meredith T.A., Gardner S., Wilson L.A. Cefazolin levels after intravitreal injection. Effects of inflammation and surgery. Invest. Ophthalmol. Vis. Sci. 1990, 31:502-505.
20. Fishman G.A., Cunha-Vaz J., Salzano T. Vitreous fluorophotometry in patients with retinitis pigmentosa. Arch. Ophthalmol. 1981, 99:1202-1207.
21. Foulds W.S., Allan D., Moseley H., Kyle P.M. Effect of intravitreal hyaluronidase on the clearance of tritiated water from the vitreous to the choroid. Br. J. Ophthalmol. 1985, 69:529-532.
22. Foy J.W., Rittenhouse K., Modi M., Patel M. Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit. J. Ocul. Pharmacol. Ther. 2007, 23:452-466.
23. Friedrich S., Cheng Y.L., Saville B. Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Curr. Eye Res. 1997, 16:663-669.
24. Fung A.E., Rosenfeld P.J., Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 2006, 90:1344-1349.
25. Gan I.M., Ugahary L.C., van Dissel J.T., van Meurs J.C. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch. Clin. Exp. Ophthalmol. 2005, 243:1186-1189.
26. Gaudreault J., Fei D., Rusit J., Suboc P., Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 2005, 46:726-733.
27. Gisladottir S., Loftsson T., Stefansson E. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:1677-1684.
28. Heegaard S., Jensen O.A., Prause J.U. Structure and composition of the inner limiting membrane of the retina. SEM on frozen resin-cracked and enzyme-digested retinas of Macaca mulatta. Graefes Arch. Clin. Exp. Ophthalmol. 1986, 224:355-360.
29. Heiduschka P., Fietz H., Hofmeister S., Schultheiss S., Mack A.F., Peters S., Ziemssen F., Niggemann B., Julien S., Bartz-Schmidt K.U., Schraermeyer U. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest. Ophthalmol. Vis. Sci. 2007, 48:2814-2823.
30. Hughes P.M. Topical delivery to the retina: reality or artifact. Angiogenesis, Exudation and Degeneration Meeting 2008, Bascom Palmer Eye Institute, Florida.
31. Hughes P.M., Olejnik O., Chang-Lin J.E., Wilson C.G. Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 2005, 57:2010-2032.
32. Iriyama A., Chen Y.N., Tamaki Y., Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br. J. Ophthalmol. 2007, 91:1230-1233.
33. Jaffe N.S. The Vitreous in Clinical Ophthalmology 1969, The C.V. Mosby Company, USA.
34. Jager R.D., Aiello L.P., Patel S.C., Cunningham E.T. Risks of intravitreous injection: a comprehensive review. Retina 2004, 24:676-698.
35. Jongebloed W.L., Worst J.F. The cisternal anatomy of the vitreous body. Doc. Ophthalmol. 1987, 67:183-196.
36. Kim J.E., Mantravadi A.V., Hur E.Y., Covert D.J. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am. J. Ophthalmol. 2008, 146:930-934. e931.
37. Kim J.H., Kim C., Lee B.J., Yu Y.S., Park K.H., Kim K.W. Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. Neurotoxicology 2008, 29:1131-1135.
38. Knudsen L.L., Dissing T., Hansen M.N., Nielsen-Kudsk F. Ocular fluorescein kinetics before and after vitrectomy on swine. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239:832-839.
39. Koeberle M.J., Hughes P.M., Skellern G.G., Wilson C.G. Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye. Pharm. Res. 2006, 23:2781-2798.
40. Lee S.S., Ghosn C., Yu Z., Zacharias L.C., Kao H., Lanni C., Abdelfattah N., Kuppermann B., Csaky K.G., D'Argenio D.Z., Burke J.A., Hughes P.M., Robinson M.R. Vitreous VEGF clearance is increased following vitrectomy. Invest. Ophthalmol. Vis. Sci. 2010, 51:2135-2138.
41. LMNO Engineering and Software, Ltd. http://www.lmnoeng.com/Volume/CylConeSphere.htm%23References.
42. Lopez-Cortes L.F., Pastor-Ramos M.T., Ruiz-Valderas R., Cordero E., Uceda-Montanes A., Claro-Cala C.M., Lucero-Munoz M.J. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 2001, 42:1024-1028.
43. Lopez-Guajardo L., Del Valle F.G., Moreno J.P., Teus M.A. Reduction of pegaptanib loss during intravitreal delivery using an oblique injection technique. Eye 2008, 22:430-433.
44. Lund-Andersen H., Sander B. The vitreous. Adler's Physiology of the Eye, tenth 2003, 293-316. Mosby Inc, USA. P.L. Kaufman, A. Alm (Eds.).
45. Lunt R. Handbook of Ultrasonic B-Scanning in Medicine 1978, Cambridge University Press Archive, Cambridge, pp. 18.
46. Majumdar S., Kansara V., Mitra A.K. Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. J. Ocul. Pharmacol. Ther. 2006, 22:231-241.
47. Mandell B.A., Meredith T.A., Aguilar E., el-Massry A., Sawant A., Gardner S. Effects of inflammation and surgery on amikacin levels in the vitreous cavity. Am. J. Ophthalmol. 1993, 115:770-774.
48. Mannermaa E., Vellonen K.S., Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug. Deliv. Rev. 2006, 58:1136-1163.
49. Maurice D.M. Injection of drugs into the vitreous body. Symposium on Ocular Therapy 1976, 59-72. John Wiley & Sons, Inc., New York. I. Leopold, R. Burns (Eds.).
50. Maurice D. Review: practical issues in intravitreal drug delivery. J. Ocul. Pharmacol. Ther. 2001, 17:393-401.
51. Maurice D.M., Mishima S. Ocular pharmacokinetics. Handbook of Experimental Pharmacology: Pharmacology of the Eye 1984, 19-116. Springer-Verlag, Berlin. M.L. Sears (Ed.).
52. Meredith T.A. Intravitreal antimicrobials 2006, 85-93. Intraocular Drug Delivery, Taylor and Francis, UK. G.J. Jaffe, P. Ashton, P.A. Pearson (Eds.).
53. Meredith T.A., Aguilar H.E., Shaarawy A., Kincaid M., Dick J., Niesman M.R. Vancomycin levels in the vitreous cavity after intravenous administration. Am. J. Ophthalmol. 1995, 119:774-778.
54. Missel P.J. Hydraulic flow and vascular clearance influences on intravitreal drug delivery. Pharm. Res. 2002, 19:1636-1647.
55. Mitchell P., Korobelnik J.F., Lanzetta P., Holz F.G., Pruente C., Schmidt-Erfurth U.M., Tano Y., Wolf S. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br. J. Ophthalmol. 2010, 94:2-13.
56. Moldow B., Larsen M., Sander B., Lund-Andersen H. Passive permeability and outward active transport of fluorescein across the blood-retinal barrier in early ARM. Br. J. Ophthalmol. 2001, 85:592-597.
57. Moldow B., Sander B., Larsen M., Engler C., Li B., Rosenberg T., Lund-Andersen H. The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch. Clin. Exp. Ophthalmol. 1998, 236:881-889.
58. Moldow B., Sander B., Larsen M., Lund-Andersen H. Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB. Invest. Ophthalmol. Vis. Sci. 1999, 40:1770-1775.
59. Moseley H., Foulds W.S., Allan D., Kyle P.M. Routes of clearance of radioactive water from the rabbit vitreous. Br. J. Ophthalmol. 1984, 68:145-151.
60. Ogura Y., Tsukada T., Negi A., Honda Y. Integrity of the blood-ocular barrier after intravitreal gas injection. Retina 1989, 9:199-202.
61. Oguro Y., Tsukahara Y., Saito I., Kondo T. Estimation of the permeability of the blood-retinal barrier in normal individuals. Invest. Ophthalmol. Vis. Sci. 1985, 26:969-976.
62. Park J., Bungay P.M., Lutz R.J., Augsburger J.J., Millard R.W., Sinha Roy A., Banerjee R.K. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J. Control Release 2005, 105:279-295.
63. Peeters L., Sanders N.N., Braeckmans K., Boussery K., Van de Voorde J., De Smedt S.C., Demeester J. Vitreous: a barrier to nonviral ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 2005, 46:3553-3561.
64. Pflugfelder S.C., Hernandez E., Fliesler S.J., Alvarez J., Pflugfelder M.E., Forster R.K. Intravitreal vancomycin. Retinal toxicity, clearance, and interaction with gentamicin. Arch. Ophthalmol. 1987, 105:831-837.
65. Pitkanen L., Pelkonen J., Ruponen M., Ronkko S., Urtti A. Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model. AAPS J. 2004, 6:e25.
66. Prager T.C., Chu H.H., Garcia C.A., Anderson R.E. The influence of vitreous change on vitreous fluorophotometry. Arch. Ophthalmol. 1982, 100:594-596.
67. Richtig E., Langmann G., Mullner K., Richtig G., Smolle J. Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas. Eye 2004, 18:619-623.
68. Rodrigues E.B., Meyer C.H., Grumann A., Shiroma H., Aguni J.S., Farah M.E. Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am. J. Ophthalmol. 2007, 143:1035-1037.
69. Rosenfeld P.J., Schwartz S.D., Blumenkranz M.S., Miller J.W., Haller J.A., Reimann J.D., Greene W.L., Shams N. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005, 112:1048-1053.
70. Sander B., Larsen M., Moldow B., Lund-Andersen H. Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. Invest. Ophthalmol. Vis. Sci. 2001, 42:433-438.
71. Schindler R.H., Chandler D., Thresher R., Machemer R. The clearance of intravitreal triamcinolone acetonide. Am. J. Ophthalmol. 1982, 93:415-417.
72. Short B.G. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 2008, 36:49-62.
73. Singh S., Stewart J.M. Intraocular bevacizumab for iris neovascularization in a silicone oil-filled eye. Retin. Cases Brief. Rep 2008, 2:253-255.
74. Spitzer M.S., Wallenfels-Thilo B., Sierra A., Yoeruek E., Peters S., Henke-Fahle S., Bartz-Schmidt K.U., Szurman P. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br. J. Ophthalmol. 2006, 90:1316-1321.
75. Stay M.S., Xu J., Randolph T.W., Barocas V.H. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm. Res. 2003, 20:96-102.
76. Tan, L.E., 2009. Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran and fluorescent microparticles. In: ARVO Summer Eye Research Conference, NIH, Bethseda, USA.
77. Wu L., Martinez-Castellanos M.A., Quiroz-Mercado H., Arevalo J.F., Berrocal M.H., Farah M.E., Maia M., Roca J.A., Rodriguez F.J. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:81-87.
78. Xu J., Heys J.J., Barocas V.H., Randolph T.W. Permeability and diffusion in vitreous humor: implications for drug delivery. Pharm. Res. 2000, 17:664-669.
79. Yoshida A., Furukawa H., Delori F.C., Bursell S.E., Trempe C.L., McMeel J.W. Effect of vitreous detachment on vitreous fluorophotometry. Arch. Ophthalmol. 1984, 102:857-860.
80. Zhu Q., Ziemssen F., Henke-Fahle S., Tatar O., Szurman P., Aisenbrey S., Schneiderhan-Marra N., Xu X., Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008, 115:1750-1755.